BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33641042)

  • 1. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
    Hassan A; Pestana RC; Parkes A
    Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.
    Miao R; Wang H; Jacobson A; Lietz AP; Choy E; Raskin KA; Schwab JH; Deshpande V; Nielsen GP; DeLaney TF; Cote GM; Hornicek FJ; Chen YE
    Radiother Oncol; 2019 Aug; 137():61-70. PubMed ID: 31078939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment options for malignant peripheral nerve sheath tumors.
    Bradford D; Kim A
    Curr Treat Options Oncol; 2015 Mar; 16(3):328. PubMed ID: 25777573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
    Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
    Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.
    Grobmyer SR; Reith JD; Shahlaee A; Bush CH; Hochwald SN
    J Surg Oncol; 2008 Mar; 97(4):340-9. PubMed ID: 18286466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant peripheral nerve sheath tumor: models, biology, and translation.
    Somatilaka BN; Sadek A; McKay RM; Le LQ
    Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.
    Martin E; Lamba N; Flucke UE; Verhoef C; Coert JH; Versleijen-Jonkers YMH; Desar IME
    Crit Rev Oncol Hematol; 2019 Jun; 138():223-232. PubMed ID: 31092379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.
    Reuss DE; Habel A; Hagenlocher C; Mucha J; Ackermann U; Tessmer C; Meyer J; Capper D; Moldenhauer G; Mautner V; Frappart PO; Schittenhelm J; Hartmann C; Hagel C; Katenkamp K; Petersen I; Mechtersheimer G; von Deimling A
    Acta Neuropathol; 2014 Apr; 127(4):565-72. PubMed ID: 24464231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.
    Park SJ; Sawitzki B; Kluwe L; Mautner VF; Holtkamp N; Kurtz A
    BMC Med; 2013 Apr; 11():109. PubMed ID: 23618374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.
    Katz D; Lazar A; Lev D
    Expert Rev Mol Med; 2009 Oct; 11():e30. PubMed ID: 19835664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.
    Moretti VM; Crawford EA; Staddon AP; Lackman RD; Ogilvie CM
    Am J Clin Oncol; 2011 Aug; 34(4):417-21. PubMed ID: 20838322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
    Ferner RE; Gutmann DH
    Cancer Res; 2002 Mar; 62(5):1573-7. PubMed ID: 11894862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant peripheral nerve sheath tumors.
    Farid M; Demicco EG; Garcia R; Ahn L; Merola PR; Cioffi A; Maki RG
    Oncologist; 2014 Feb; 19(2):193-201. PubMed ID: 24470531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.